| scholarly article | Q13442814 |
| P2093 | author name string | Stefano Lepore | |
| Antonio Colombo | |||
| Carlo Briguori | |||
| Erminio Bonizzoni | |||
| Flavio Airoldi | |||
| Amelia Focaccio | |||
| Bruno Golia | |||
| Bruno Ricciardelli | |||
| Mariateresa Librera | |||
| Anna Violante | |||
| Guido Riviezzo | |||
| Pasquale Balestrieri | |||
| Pierfranco Scarpato | |||
| Pietro Paolo Elia | |||
| P433 | issue | 20 | |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 1822-1828 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction | |
| P478 | volume | 25 |
| Q37953885 | 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi |
| Q53175089 | A Randomized Trial of Creatine-kinase Leak After Rosuvastatin in Elective Percutaneous Coronary Intervention (CLEAR-PCI). |
| Q35919438 | Angiotensin type 1 receptor A1166C gene polymorphism is associated with endothelial dysfunction and in-stent restenosis after percutaneous coronary intervention |
| Q37409610 | Association of chronic kidney disease with periprocedural myocardial injury after elective stent implantation: A single center prospective cohort study |
| Q90169905 | Atorvastatin Reduces In Vivo Fibrin Deposition and Macrophage Accumulation, and Improves Primary Patency Duration and Maturation of Murine Arteriovenous Fistula |
| Q38861711 | Biodegradable Polymers Influence the Effect of Atorvastatin on Human Coronary Artery Cells |
| Q41987041 | Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study. |
| Q38099287 | Defining the role of high-dose statins in PCI. |
| Q37941867 | Do statins have a role in reduction/prevention of post-PCI restenosis? |
| Q61445734 | Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies |
| Q38600680 | Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis |
| Q38437548 | Effect of previous statin therapy in patients with acute coronary syndrome and percutaneous coronary intervention |
| Q43722133 | Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis |
| Q53741454 | Effects of Qishen Yiqi Dripping Pills () in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study. |
| Q37434520 | Effects of atorvastatin loading prior to primary percutaneous coronary intervention on endothelial function and inflammatory factors in patients with ST-segment elevation myocardial infarction |
| Q60912594 | Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial |
| Q38699009 | Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion |
| Q53033990 | Evidence of pleiotropy by statins: leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. |
| Q38165881 | High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: a meta-analysis of randomized controlled trials |
| Q37466728 | High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention |
| Q34634358 | High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials |
| Q55035469 | Impact of Intracoronary Adenosine on Myonecrosis in Patients with Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention. |
| Q41632953 | Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial |
| Q58973214 | Marked Improvements in Outcomes of Contemporary Percutaneous Coronary Intervention in Patients with Diabetes Mellitus |
| Q34962673 | Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition |
| Q39165368 | Observational Prospective study to esTIMAte the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins -follow-up (OPTIMA II). |
| Q46662890 | Occurrence of non-Q wave myocardial infarction following percutaneous coronary intervention in the stent era: systematic monitoring of the three markers of myocardial necrosis |
| Q36263844 | Peri-procedural myocardial injury: 2005 update |
| Q37638256 | Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention |
| Q38635408 | Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI. |
| Q37709401 | Predictive value of C-reactive protein after drug-eluting stent implantation |
| Q36915760 | Preprocedural statin therapy in percutaneous coronary intervention |
| Q43046171 | Procedure-related myonecrosis after bare and drug-eluting stent implantation |
| Q37215585 | Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention |
| Q44800910 | Protective role of statins in patients with acute coronary syndrome aged ≥ 75 years with low LDL-C who underwent percutaneous coronary intervention |
| Q35088129 | Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL. |
| Q34631845 | Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction |
| Q36837567 | Role of statins in coronary artery disease |
| Q53594601 | Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. |
| Q43740908 | Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial |
| Q46917516 | Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats |
| Q37798804 | Statin loading before percutaneous coronary intervention: proposed mechanisms and applications |
| Q41374557 | Statin treatment before percutaneous cononary intervention. |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q38025837 | Statins in acute coronary syndrome: very early initiation and benefits |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q34729472 | Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins. |
| Q37786646 | Stents and statins: history, clinical outcomes and mechanisms |
| Q34477330 | The Anti-Ischemic and Anti-Anginal Properties of Statins |
Search more.